A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes

In clinical trials, sodium-glucose co-transporter (SGLT) inhibitor use as adjunct to insulin therapy in type 1 diabetes (T1D) provides glucometabolic benefits while diabetic ketoacidosis risk is increased. The SGLT2 inhibitor empagliflozin was evaluated in two phase III trials: EASE-2 and EASE-3. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnston, Curtis K., Eudy-Byrne, Rena J., Elmokadem, Ahmed, Nock, Valerie, Marquard, Jan, Soleymanlou, Nima, Riggs, Matthew M., Liesenfeld, Karl-Heinz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8066500/
https://www.ncbi.nlm.nih.gov/pubmed/33918261
http://dx.doi.org/10.3390/pharmaceutics13040485

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8066500/
https://www.ncbi.nlm.nih.gov/pubmed/33918261
http://dx.doi.org/10.3390/pharmaceutics13040485

Ejemplares similares